Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Senior editor
Washington DC, USA
42+ years of experience
Pink Sheet
By Cathy Kelly 07 Jan 2021
Razor-thin majorities in both chambers of Congress mean Democrats can’t enact a bold agenda, and the pandemic and attendant recession mean that the initial legislative focus won’t be on Rx issues.
Pink Sheet
By Cathy Kelly 18 Nov 2020
Regardless of the outcomes of the US elections, drug pricing is likely to take a back seat to COVID as policy focus. But the pandemic does offer pharma an opportunity for partnerships with payers on health outcomes. Commonwealth Fund’s Liz Fowler, South Capitol’s John O’Brien and ICER’s Steve Pearson discuss where drug pricing stands in public opinion, whether policies embraced by President Trump will have staying power, and the conditions needed in the policy environment for major change.
Pink Sheet
By Cathy Kelly 18 Nov 2020
A Biden Administration with near-term priorities other than drug pricing and a Republican-controlled Senate dedicated to blocking any legislation that would enact government price controls is a relatively positive outcome for industry
Topic US Election 2020 Drug Pricing
Pink Sheet
By Cathy Kelly 17 Nov 2020
Germany uses government facilitated price negotiations between publicly funded insurers and manufacturers that are based on an independent assessment of how much added value a drug provides.
Topic US Election 2020 Drug Pricing
Pink Sheet
By Cathy Kelly 25 Sep 2020
Center for American Progress suggests pricing reforms for the 'next Administration' in lieu of legislation.
Topic US Election 2020 Drug Pricing
Pink Sheet
By Cathy Kelly 21 Sep 2020
Outgoing Biotechnology Innovation Organization CEO suggests consideration of price inflation caps instead of 'big discounts' in Medicare Part D and says that industry should fund a cap on beneficiary out-of-pocket costs in the program.
Pink Sheet
By Cathy Kelly 21 Sep 2020
Industry balks at President Trump’s latest effort to force biopharma to negotiate a drug pricing solution, but investors may be pushing for concessions that could head off more onerous policies supported by a Biden White House.
Pink Sheet
By Cathy Kelly 02 Apr 2020
Guidelines for US health care providers could help prevent shortages as demand for possible treatments surge, groups say. Stakeholders also argue “Buy America” executive order would hamper drug access.
Topic Coronavirus
Pink Sheet
By Cathy Kelly 18 Dec 2019
Bill addresses ‘dead zone’ for pending applications for protein products transitioning to biologic status; generic and brand industries each win in different legislative provisions: inclusion of the CREATES Act, and a revised definition for ‘biologics’ that includes chemically synthesized polypeptides.
Topic Biosimilars Legislation
Pink Sheet
By Cathy Kelly 09 Aug 2019
Investigation may help define when rebate arrangements seeking to protect a brand against biosimilar competition are anticompetitive.
Topic Policy & Regulation
Pink Sheet
By Cathy Kelly 26 Jul 2019
Price inflation rebates are expected to generate $50bn in savings over 10 years, according to the Congressional Budget Office.
Pink Sheet
By Cathy Kelly 02 Jul 2019
Reform "is going to happen,” promised Energy & Commerce Oversight Subcommittee Chair Diana DeGette, suggesting the panel’s next hearing on insulin price reform may be held in July.
Topic Diabetes
Pink Sheet
By Cathy Kelly 26 Jun 2019
Finance Committee chairman wants a provision allowing Medicaid to make installment payments for high-cost curative treatments in drug pricing legislation. But Democrats worry such a model might encourage high prices.
Topic Policy & Regulation
Scrip
By Cathy Kelly 22 Mar 2019
Public statements by Novartis and Avexis suggest Zolgensma could be cost effective at a price up to $5m. Analysts expect $2m. The lower estimate is still stunning, but could it be considered reasonable by comparison?
Topic Drug Review Approvals
Pink Sheet
By Cathy Kelly 01 Feb 2019
Proposed US rule would establish two new safe harbors against anti-kickback enforcement, one covering price reductions at the point of sale and the other protecting flat service fees paid by manufacturers to pharmacy benefit managers. But rebates to "PBMs to buy formulary position" in Medicare/Medicaid would lose protection.
Pink Sheet
21 Jul 2022
Pink Sheet
13 Jul 2022
Pink Sheet
12 Jul 2022
Scrip
07 Jul 2022
Pink Sheet
05 Jul 2022
Pink Sheet
05 Jul 2022
Pink Sheet
29 Jun 2022
Pink Sheet
23 Jun 2022
Pink Sheet
22 Jun 2022
Generics Bulletin
21 Jun 2022
Pink Sheet
21 Jun 2022
Pink Sheet
20 Jun 2022
Pink Sheet
15 Jun 2022
Pink Sheet
13 Jun 2022
Scrip
08 Jun 2022
